Article Text

Download PDFPDF
Tc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer
  1. Kanhaiyalal Agrawal1,
  2. P Sai Sradha Patro1 and
  3. C Preetam2
  1. 1 Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
  2. 2 ENT, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
  1. Correspondence to Dr Kanhaiyalal Agrawal, nucmed_kanhaiyalal{at}


There is literature evidence showing utility of somatostatin receptor (SSTR) positron emission tomography-CT (PET-CT) imaging in differentiated thyroid cancer with Thyroglobulin Elevated and Negative Iodine Scan (TENIS). These patients are less benefited with I-131 therapy and surgery remains only curable option if disease could be localised. If surgery is not feasible, other therapeutic options are not promising. However, if these patients show strongly positive SSTR imaging, then possibility of peptide receptor radionuclide therapy may be explored. As SSTR PET-CT imaging is expensive and not widely available, Technetium-99m (Tc-99m) hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC), which is a Single photon emission computed tomography (SPECT) tracer, can be used. We are documenting a case of raised serum thyroglobulin antibody and negative I-131 whole body scan with disease recurrence localised on Tc-99m HYNIC-TOC scan.

  • thyroid disease
  • endocrine system
  • thyroid cancer
  • dedifferentiated

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors KA: conception or design of the work, analysis or interpretation of data, drafting the work and final approval. PSP: drafting the work and final approval. CP: revising it critically and final approval.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.